naxitamab
6 abstracts
Abstract
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.Org: Hospital Sant Joan de Deu,
Abstract
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine, Riley Hospital for Children,
Abstract
Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine,
Abstract
Reduction in Curie score in neuroblastoma patients treated with naxitamab.Org: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Hong Kong Children's Hospital, The University of Hong Kong, The Hospital for Sick Children,
Abstract
Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease.Org: Memorial Sloan Kettering Cancer Center,